Interest in and Preference for Long-acting Injectable Antiretroviral Therapy in the Era of Approved Cabotegravir/Rilpivirine among Reproductive-aged Women in the U.S. South

Clin Infect Dis. 2024 Jun 29:ciae331. doi: 10.1093/cid/ciae331. Online ahead of print.

Abstract

Among 103 reproductive-aged women with HIV in the U.S. South surveyed post-approval of long-acting injectable (LAI) cabotegravir/rilpivirine, nearly two-thirds reported willingness to try LAI antiretroviral therapy (ART). Most expressed preference for LAI over daily oral ART and had minimal concerns over potential LAI-ART use impacting reproductive health.

Keywords: HIV and pregnancy; Southern HIV/AIDS epidemic; cabotegravir/rilpivirine; long-acting injectable antiretroviral therapy; women with HIV.